In a report released on January 21, Brian Abrahams from RBC Capital maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), ...

Investment analysts at Leerink Partnrs upped their FY2024 earnings per share (EPS) estimates for Sarepta Therapeutics in a report issued on Monday, January 20th. Leerink Partnrs analyst J. Schwartz ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price ...

We came across a bullish thesis on Sarepta Therapeutics, Inc. (SRPT) on Disruptive analytics’ Substack by Magnus Ofstad. In ...

Analysts at HC Wainwright raised their FY2024 earnings estimates for Sarepta Therapeutics in a note issued to investors on ...

Sarepta Therapeutics' Elevidys for DMD shows revenue potential, with market cap justified at $11.4bn and potential for >50% ...

A report questions the FDA's accelerated approval process citing Sarepta and Biogen therapies as examples. Read more here.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $151.64, a high estimate of ...

In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other gene therapy stocks. Gene therapy is referred to as a medical technique that ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported ...

SRPT) is up by about 0.7%. For a complete list of holdings, visit the LABU Holdings page » The chart below shows the one year price performance of LABU, versus its 200 day moving average ...